Navigation Links
K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
Date:9/10/2010

li>
  • the impact of competitive response to the Company's sales, marketing and strategic efforts, including introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries;
  • risks that the Company may not ultimately prevail in litigation, including product liability lawsuits and challenges to its intellectual property rights by actual or potential competitors or to its ability to market generic products due to brand company patents and challenges to other companies' introduction or potential introduction of generic or competing products by third parties against products sold by the Company or its subsidiaries including without limitation the litigation and claims referred to in Note 18 – "Commitments and Contingencies" of the Notes to the Consolidated Financial Statements in the Form 10-Q, and that any adverse judgments or settlements of such litigation, including product liability lawsuits, may be material to the Company;
  • the possibility that our current estimates of the financial effect of certain announced product recalls could prove to be incorrect;
  • whether any product recalls or product introductions result in litigation, agency action or material damages;
  • failure to supply claims by certain of the Company's customers, including CVS Pharmacy, Inc., that, despite the formal discontinuation action by the Company of its products, the Company should compensate such customers for any additional costs they allegedly incurred for procuring products the Company did not supply;
  • the satisfaction or waiver of the terms and conditions for the acquisition of the full U.S. and worldwide rights to Gestiva™ set forth in the previously disclosed Gestiva™ acquisition agreement, as amended;
  • the series of putative class action lawsuits alleging violations of the federal securities laws by the Company and certain individuals, as more fully described i
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/2/2015)...   , July 2, 2015 BGI ... Hong Kong has been accredited ... Kong facility is the first clinical next-generation-sequencing laboratory to ... , meeting the highest standard in clinical laboratory practices. Complementary ... 11 compliant laboratory process, and multiple ISO certifications, the ...
    (Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
    (Date:7/1/2015)... -- Eli Lilly and Company (NYSE: LLY ) will ... on Thursday, July 23, 2015. Lilly will also conduct a ... media to further detail the company,s financial performance. ... media and the general public can access a live webcast ... posted on Lilly,s website at www.lilly.com . A replay ...
    Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
    ... Mylan Inc. (Nasdaq: MYL ) today ... entered into a settlement agreement with Warner Chilcott resolving ... as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 ... mg (28-Day Regimen). This medication is an oral contraceptive. ...
    ... NEW YORK, Oct. 19, 2011 Reportlinker.com announces ... in its catalogue: Syncria ... 2020 http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Forecasts to 2020 Summary ...
    Cached Medicine Technology:Mylan Announces Femcon® Fe Settlement Agreement 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
    (Date:7/2/2015)... , ... July 02, 2015 , ... After conducting a ... Yuma Regional Medical Center in Yuma, Ariz., has hired Robert Trenschel, DO, ... healthcare and medical management, Dr. Trenschel will assume his new duties at Yuma Regional ...
    (Date:7/2/2015)... ... July 02, 2015 , ... The report ... Capsule manufacturers. The report is a valuable source of guidance and direction for ... and Chinese market for the Gelatin Capsule industry including capacity, production, production value, ...
    (Date:7/2/2015)... ... July 02, 2015 , ... ... is announcing with their launch an intention to partner with companies that share ... on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic ...
    (Date:7/2/2015)... AL (PRWEB) , ... July 02, 2015 , ... Every year, DUI arrests and fatalities ... July may be the deadliest day of the year when it comes to being on ... “The National Highway Traffic Safety Association reports that 40% of all highway deaths between 2007 ...
    (Date:7/2/2015)... ... 2015 , ... Today, East Liverpool City Hospital announced Pam Akin, RN, MSN, ... Hospital (ELCH). Pam is currently the Chief Nursing Officer at ELCH and will remain ... a master’s degree in health care administration as well as nursing. She has a ...
    Breaking Medicine News(10 mins):Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:Attorney David Maloney Stresses Safety through Sobriety 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3
    ... Francisco Bay Area Affiliate of Susan G. Komen for the ... to applaud the introduction of the 21st Century Cancer ALERT ... Detection, R esearch and T reatment) Act, bipartisan ... and Kay Bailey Hutchison (R-TX). "It,s been more than ...
    ... from fertility clinic embryos that otherwise would be discarded ... to use U.S. funding for embryonic stem cell research ... would be discarded, the National Institutes of Health announced ... research -- such as using stem cells taken from ...
    ... April 17 Even though suicide outranks homicide as ... death certificates thwart healthcare policymakers who want to create ... a WVU study shows."The Institute of Medicine ... have been diagnosed with a mental disorder, but death ...
    ... United States Great Depression of 1929 has the American ... well-being across the parameters of occupational, spiritual, emotional, and ... people are at risk for suffering lowered self esteem, ... St. Thomas University Counseling Programs - initiated ...
    ... Penny Imaging Exchange has acquired new German technology to process the ... ... Bohemia, NY (Vocus) April 17, 2009 -- Penny Imaging ... the conversion of microfiche records to digital form - the ...
    ... (Nasdaq: SUAI ) ("SUA" or the ... leading independent proxy advisory firm, has recommended that stockholders vote ... nominees recommended by dissident stockholder Hallmark Financial Services, Inc. ("Hallmark"). ... 9:00 a.m. local time on May 5, 2009 at 222 ...
    Cached Medicine News:Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 2Health News:San Francisco Bay Area Affiliate of Susan G. Komen for the Cure(R) Applauds Introduction of Bipartisan Cancer Alert Act 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 2Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 3Health News:NIH May Ease Some, But Not All, Stem Cell Restrictions 4Health News:Team Uncovers Discrepancy in Death Certificates Listing Suicide 2Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 2Health News:Leading Independent Proxy Advisory Firm Supports Specialty Underwriters' Alliance, Inc. in Its Proxy Contest Against Hallmark Financial Services, Inc. 3
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: